Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03518073
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date April 30, 2018
Completion date October 25, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Completed NCT04566003 - Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Recruiting NCT05395624 - Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers Phase 1/Phase 2